Arcus Biosciences News and Activities

Arcus Biosciences is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Arcus Biosciences is a company listed under the stock ticker RCUS (US).

View the org chart displaying its 28 main executives

Most searched biographies at Arcus Biosciences

• Terry Rosen, Chief Executive Officer and Director
• Merdad Parsey, Director
• Kathryn Falberg, Director

Popular executive movements at Arcus Biosciences

• Eric Matthews, Chief Commercial Officer, has left the company  (posted on May 8 2025).
• Dimitry Nuyten, Chief Medical Officer, will leave the company on Jan. 31, 2025  (posted on January 22 2025).
• Richard Markus will join the company as Chief Medical Officer on Jan. 31, 2025  (posted on January 22 2025).

Create your alert
to follow the executive moves at Arcus Biosciences.

Arcus Biosciences has 2,338 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (posted on April 30 2025)..
• Deepull has just announced a $50 Million fundraising (posted on April 29 2025).
• Biolinq has just announced a $100 Million fundraising (posted on April 23 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Herriot Tabuteau - Chief Executive Officer and Director at Axsome Therapeutics

Learn more about the Biotechnology industry

Press releases by Arcus Biosciences

• Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
• Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
• Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
• Arcus Biosciences to Participate in Two Upcoming Investor Conferences
• Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update
• Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium
• Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
• Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
• New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
• Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer
• View more press releases Close

Social media about Arcus Biosciences

• Arcus Biosciences on Wikipedia, Google News & Yahoo Finance
• Arcus Biosciences on LinkedIn, Twitter & YouTube